ArticleTranslational vision science & technology2025
Optimizing the Potential Utility of Blue-Blocking Glasses for Sleep and Circadian Health.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of blue-light blocking glasses on actigraphic sleep outcomes: a systematic review and meta-analysis of randomized controlled crossover trials.Frontiers in neurology · 2025Pooled it
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Wearable filters that reduce light in the short wavelength region of the visible spectrum, or "blue-blocking glasses," are increasingly available and offer an individualized, low-cost tool for enhancing sleep and circadian health. However, their effectiveness depends on filtering properties, application, timing, and implementation. If these factors are disregarded, blue-blocking glasses may be ineffective or lead to counterproductive outcomes. Methods: We introduce a new metric, melanopic daylight filtering density (mDFD), to quantify a filter's capacity to decrease melanopic input, providing an alternative to ad-hoc measures. We applied mDFD to 26 commercially available glasses, estimating their potential to reduce circadian and related physiological effects of light across common applications in the context of consensus-based metrics and recommendations. We also reviewed intervention studies that used blue-blocking glasses. Results: Products varied considerably in mDFD, with only those rated at mDFD ≥1 providing sufficient reductions in melanopic input to justify the "blue-blocking" label and associated claims. At least one relevant sleep or circadian-related outcome improved with blue-blocking interventions in the studies reviewed. In addition to filtering strength, appropriate timing and usage are critical to effectiveness. Conclusions: The efficacy of blue-blocking glasses depends on both spectral filtering and proper usage. The mDFD metric offers a consistent, evidence-based approach for evaluating, selecting, and designing products that reduce photic input for non-visual physiological effects of light. Translational Relevance: Standardized characterization of blue-blocking glasses using mDFD facilitates reliable product comparisons, evidence-based selection, and rational design of lenses that are optimized for circadian health across a range of applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.